Branded vial and pen-kit presentation. Confirm the available format, contents and packaging for this product.
Tesamorelin
A growth hormone-releasing hormone analogue studied in endocrine signalling.
Listed content per unit- Presentation
- Vial presentation
- Local dispatch markets
- Australia · Canada · USA
- Availability
- Confirm by strength & location
- Documentation
- Request product & batch records
For qualified research enquiries. Listed content is not a dose or administration instruction.
The research context
Tesamorelin is a growth hormone-releasing factor analogue. It is relevant to research involving pituitary signalling and associated metabolic pathways.
The approved prescription medicine Egrifta has a specific indication for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label states it is not indicated for weight-loss management; its approval does not apply to Aurelis material.
What does Tesamorelin do?
Read our Tesamorelin guide for a simple explanation of abdominal-fat and growth-hormone research and what studies found.
What to include in your enquiry
Tell us your required compound, strength, presentation and destination country. If you have a particular analytical requirement, include the method or document you need so the team can match your request to the relevant specification.
Selected scientific references
These sources describe published research or a specific regulated medicine. They are not certificates for an Aurelis batch.
Connect with Aurelis
Your next enquiry
starts with the details.
Tell us the compound, listed content, preferred presentation and destination. Our team can discuss local availability and the documentation for your selected material.